(VVOS) Vivos Therapeutics, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(VVOS) Vivos Therapeutics, Inc. Complete Analysis Pack
Vivos Therapeutics Business Model Canvas: Strategic Growth in Healthcare
Unlock the full strategic blueprint behind Vivos Therapeutics, Inc.’s business model. This concise Business Model Canvas reveals how the company creates value, serves key customer segments, and supports growth in a specialized healthcare market. Ideal for investors, analysts, and entrepreneurs seeking actionable insight—get the full version to see the complete picture.
Partnerships
Licensed general dentists
Vivos Therapeutics, Inc. sells the Vivos System to licensed general dentists, who are the main clinical users and purchase channel in the United States and Canada. These dentists screen patients, fit the device, and deliver treatment in-office, so Vivos depends on their clinical adoption and referral flow to drive revenue and recurring patient starts.
Sleep physicians and referrers
Obstructive sleep apnea affects about 1 billion people worldwide, and up to 80% of cases go undiagnosed, so Vivos Therapeutics, Inc. depends on sleep physicians and other referrers to find, diagnose, and co-manage patients. These partnerships also support treatment coordination and follow-up in a shared-oversight care path.
Dental practices and DSOs
Dental practices are the core operating sites where Vivos Therapeutics, Inc. delivers its system, so provider training and chairside use directly affect adoption. Dental service organizations can speed rollout across many locations at once, helping expand patient access and raise provider utilization faster than single-site selling.
Home sleep test providers
Vivos Therapeutics, Inc. uses home sleep test providers to make VivoScore screening easier, because third-party testing can confirm sleep-related conditions without an in-lab study. That matters in a market where about 80% of moderate-to-severe obstructive sleep apnea cases are still undiagnosed, so lower-friction testing can speed patient routing and treatment.
- Supports VivoScore home testing
- Reduces clinic friction
- Helps confirm sleep conditions faster
Clinical education partners
Clinical education partners help Vivos Therapeutics, Inc. train dentists, orthodontists, and sleep-medicine clinicians so the company’s multi-disciplinary therapy is used consistently and correctly. Research-focused partners also strengthen clinical credibility by supporting evidence generation and peer-facing adoption across care settings.
- Boosts clinician training
- Supports proper use
- Builds clinical evidence
- Improves adoption
Vivos’ Growth Hinges on Key Sleep Care Partners
Vivos Therapeutics, Inc. relies on dentists, sleep physicians, home sleep test providers, and clinical educators to find patients, confirm diagnosis, and deliver care. These partners matter in a market where about 1 billion people have obstructive sleep apnea and up to 80% of cases go undiagnosed, so referral flow and testing access directly shape adoption.
| Partner | Role | Data point |
|---|---|---|
| Dentists | Sell and treat | Core in-office channel |
| Sleep physicians | Diagnose and co-manage | Up to 80% undiagnosed |
| Home test providers | Screen patients | 1 billion affected |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for Vivos Therapeutics, Inc., covering its customers, channels, value proposition, and revenue model.
Customizable Excel Spreadsheet
Quickly spot Vivos Therapeutics’ key business drivers and pain points in one clear, editable snapshot.
Reference Sources
Vivos Therapeutics, Inc. Reference Sources provide a clear, traceable evidence trail that boosts credibility and speeds decision-making.
Activities
Product development
Vivos Therapeutics, Inc. focuses product development on the Vivos System, refining it for dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring, while keeping design tied to real clinical use. OSA affects about 1 billion adults worldwide, so product work must support steady upgrades, safety, and lifecycle management that clinicians can use in practice.
Commercialization to providers
Vivos Therapeutics, Inc. sells and distributes its system to licensed medical professionals, with commercialization focused on general dentists in the United States and Canada. The main work is direct provider acquisition and practice expansion, so growth depends on adding new dentists and increasing use within existing practices.
VivoScore screening
VivoScore screening and home sleep testing help Vivos Therapeutics, Inc. spot adults and children who may need care early; obstructive sleep apnea affects about 1 billion people worldwide, so screening is a large entry point. It also feeds the treatment funnel, moving patients from first check into Vivos Therapeutics, Inc.'s broader care ecosystem.
Clinician training
Clinician training is a core activity for Vivos Therapeutics, Inc. because the system only works well when providers know the protocol, patient selection, and follow-up steps. Strong onboarding and ongoing support lift adoption and keep treatment delivery consistent across practices.
- Onboard providers before first case
- Teach protocol and patient selection
- Support ongoing case execution
- Improve adoption and consistency
Clinical validation and compliance
Clinical validation and compliance are core to Vivos Therapeutics, Inc., because medical trust depends on proof, not claims. Ongoing evidence generation, quality oversight, and regulatory control help keep its therapy credible with dentists, physicians, and patients.
- Build clinical evidence continuously
- Track quality and safety closely
- Meet regulatory and compliance rules
- Protect trust with providers and patients
Vivos Drives OSA Growth Through Product, Training, and Screening
Vivos Therapeutics, Inc. centers key work on product development, clinician training, and care delivery for OSA and snoring. With OSA affecting about 1 billion adults worldwide, Vivos Therapeutics, Inc. must keep improving the Vivos System, screening flow, and provider onboarding so use stays consistent in real practices.
| Key activity | Why it matters |
|---|---|
| Product development | Upgrade Vivos System |
| Provider training | Support protocol use |
| Screening | Feed treatment pipeline |
Full Document Unlocks After Purchase
Business Model Canvas
This Vivos Therapeutics, Inc. Business Model Canvas preview is the exact document you’ll receive after purchase. It’s not a sample or mockup—what you see here is a direct snapshot of the final file. Once you buy it, you’ll get the same fully formatted content, ready to edit, present, or share.
Resources
Vivos System IP
The Vivos System IP is a core asset for Vivos Therapeutics, Inc., because its device know-how and protected treatment methods help set the brand apart in oral appliance therapy. This IP underpins the company’s treatment platform and supports its market position as it scales clinical use and recurring provider adoption.
VivoScore platform
VivoScore is Vivos Therapeutics, Inc.'s screening and home sleep testing service resource, so it extends the Company Name beyond devices into diagnostics support. That matters in a market where an estimated 936 million adults worldwide had obstructive sleep apnea in the latest large-scale global study, helping providers build a steadier patient pipeline.
Provider network
Vivos Therapeutics, Inc. depends on licensed medical professionals, with general dentists as its main distribution base, to prescribe and deliver its oral appliance therapy. That network gives Vivos direct patient access and repeat clinical use, which supports recurring revenue as treatments move through the provider channel.
Clinical protocols and data
Clinical protocols and data are core key resources for Vivos Therapeutics, Inc. because a multi-disciplinary model needs standardized, repeatable treatment steps across providers. Clinical evidence also supports provider confidence and helps position the products by showing how outcomes are validated and when to use them.
- Standardizes care across providers
- Supports outcome validation
- Strengthens product credibility
Sales and support organization
Vivos Therapeutics, Inc.'s sales and support organization is a key adoption engine because provider-facing teams handle onboarding, training, and follow-up, turning clinical interest into active use. In FY2025, this matters as the company scales a recurring provider network model, where retention and repeat engagement can be as important as first-time sales.
- Onboards providers fast
- Trains on clinical use
- Maintains relationship continuity
- Converts interest to usage
Vivos’ IP Powers a Scalable OSA Care Model
Vivos Therapeutics, Inc. relies on IP, clinical protocols, provider training, and diagnostics like VivoScore to turn oral appliance therapy into a repeatable care model. Its resource base matters in a market where about 936 million adults worldwide had obstructive sleep apnea in the latest large-scale global study.
| Key resource | Data |
|---|---|
| OSA market | 936M adults |
| Channel | Dentist-led |
| Core asset | Vivos System IP |
Value Propositions
Non-invasive therapy
The Vivos System offers a non-invasive option for adults who want to avoid surgery, which matters because more than 1 billion adults worldwide are estimated to have obstructive sleep apnea. A gentler path can reduce hesitation around aggressive interventions and help more patients start treatment sooner.
Non-surgical and drug-free
Vivos Therapeutics, Inc. positions its therapy as non-surgical and drug-free, giving patients an option outside invasive procedures and medication-based care. That matters in a market where more than 30 million U.S. adults are estimated to have sleep apnea, and many want long-term treatment without surgery or pharmaceuticals.
OSA and snoring focus
Vivos Therapeutics targets obstructive sleep apnea and snoring, two huge sleep problems with steady treatment demand; the American Academy of Sleep Medicine estimates OSA affects about 1 billion adults worldwide. By offering a specialized oral-appliance option, Company Name sits in a care path where many patients still need alternatives to CPAP.
Adult and pediatric screening
VivoScore screens both adults and children, so Vivos Therapeutics, Inc. can reach a wider pool than adult-only care. That matters because sleep-related issues can start early, and earlier screening can lead to faster referral and treatment decisions.
- Serves adults and children
- Expands addressable market
- Supports earlier issue detection
Dentistry-led delivery
Vivos Therapeutics, Inc. sells through licensed dentists, so the treatment reaches patients inside a familiar care setting and fits existing exam, imaging, and follow-up workflows. With more than 200,000 active dentists in the U.S., this provider-led model can widen access without building a separate clinic network.
- Dentists are the main sales channel
- Fits routine dental workflows
- Uses existing patient access points
Drug-Free Sleep Apnea Care Through Dentists
Company Name offers non-surgical, drug-free care for obstructive sleep apnea and snoring, aiming to reach patients who want alternatives to CPAP, surgery, and medication. VivoScore broadens the funnel by screening adults and children, helping earlier detection and referral.
Its dentist-led model fits routine dental workflows and uses an existing care network; the U.S. has more than 200,000 active dentists, which supports access without building separate clinics.
| Value proposition | Data point |
|---|---|
| Non-invasive therapy | OSA affects 1B+ adults worldwide |
| Screening reach | Adults and children |
| Distribution | 200,000+ active U.S. dentists |
Customer Relationships
Provider onboarding
Provider onboarding at Vivos Therapeutics, Inc. starts with training and clear clinical instruction, because providers must learn the system before they can offer it. This is a highly consultative relationship, and Vivos Therapeutics, Inc.'s revenue model depends on providers adopting a specialized, physician-led treatment workflow.
Ongoing clinical support
Ongoing clinical support is key for Vivos Therapeutics, Inc. because provider adoption of medical technology depends on help with case selection, device use, and workflow questions. That support can lift retention and repeat orders, especially as the company works with a broad installed base of dental practices and orthodontic teams.
Account management
Vivos Therapeutics, Inc. uses account management to keep long-term ties with practices and groups, which helps drive repeat ordering and expand the installed base. This matters because the company’s 2025 growth still depends on turning each active practice into a larger, recurring revenue account.
Patient education support
Vivos Therapeutics, Inc. can support patient education with clear, provider-ready materials that explain sleep and dentofacial care in plain language. Better education can raise treatment acceptance and follow-through, which matters when care spans home use, visits, and long timelines.
- Patient-facing guides improve understanding
- Provider tools reduce explanation time
- Clearer care plans support adherence
Referral coordination
Referral coordination is central to Vivos Therapeutics, Inc.'s customer relationships: dentists screen patients, then medical partners help route them into treatment, which keeps the care path moving and supports follow-up. This matters in a cross-specialty model where patient progress and outcome tracking depend on timely handoffs.
- Moves patients from screening to treatment
- Links dentists and medical professionals
- Supports follow-up and outcome tracking
Consultative Care Keeps Vivos Practices Connected
Vivos Therapeutics, Inc. keeps customer ties consultative: it trains providers, supports case selection and workflow, and gives patient-ready education that helps practices explain treatment and improve adherence. Referral handoffs between dentists and medical partners also matter, since this model depends on coordinated, long-term follow-up.
| Relationship lever | Role |
|---|---|
| Provider training | Speeds adoption |
| Clinical support | Lifts retention |
| Referral coordination | Keeps care moving |
Channels
Direct provider sales
Vivos Therapeutics, Inc. sells its system directly to licensed medical professionals, with general dentists serving as the core channel in the United States and Canada. This is the main route to market, giving the Company direct control over training, adoption, and provider relationships.
Practice onboarding
Practice onboarding turns interested dental providers into active users by handling setup, training, and workflow fit. For Vivos Therapeutics, Inc., this matters because adoption in a practice depends on fast integration, clear education, and early use by the clinical team.
Professional training events
Professional training events are a key channel for Vivos Therapeutics, Inc., because clinician education drives awareness and conversion. Training sessions, webinars, and provider meetings explain the therapy clearly and can reach both new and existing dentists and sleep clinicians.
These events also support adoption by giving providers a direct path from education to use, which helps turn interest into prescriptions and practice growth.
Digital presence
Vivos Therapeutics, Inc. can use its website and digital content to drive lead capture, while also giving providers and patients clear product education. Digital channels are a low-cost way to explain the cPAP-free treatment model, show clinical use cases, and support awareness at scale.
- Website-led lead generation
- Provider education online
- Patient awareness and screening
- Efficient product explanation
Referral networks
Referral networks are a key channel for Vivos Therapeutics, Inc. because clinicians and medical partners can send patients into its sleep care pathway. In sleep-related care, where dentists, physicians, and sleep specialists often work together, these referrals help widen access across practices and support patient flow.
- Clinician referrals drive patient intake
- Medical partners expand cross-practice access
- Collaboration fits sleep care
Vivos Grows Through Direct Dental Sales, Training, and Referrals
Vivos Therapeutics, Inc. reaches licensed dental providers mainly through direct sales, practice onboarding, and clinician training, with general dentists as the core U.S. and Canada channel. Website leads and referral networks then help move providers and patients into care.
| Channel | Role |
|---|---|
| Direct provider sales | Core route to market |
| Onboarding and training | Drives adoption |
| Website and digital | Captures leads |
| Referrals | Expands patient flow |
Customer Segments
General dentists
General dentists are Vivos Therapeutics, Inc.'s core customer segment, because the Vivos System is sold to licensed dentists who deliver most patient treatment. With more than 200,000 dentists in the U.S. serving as frontline oral-health providers, this channel sits at the center of case identification, device fitting, and follow-up care.
Other licensed medical professionals
Other licensed medical professionals widen Vivos Therapeutics, Inc.’s clinical reach by helping with screening, referral, and treatment support, so the system is not limited to one provider type. In 2025, this broader provider base helps build a larger care network around airway-focused therapy and makes it easier to route patients into treatment.
Dental practices and DSOs
Dental practices and DSOs matter because one buying decision can roll out across many chairs and locations, so Vivos Therapeutics, Inc. can scale faster than with single offices. DSOs already represent about 20% of U.S. dentists, giving Vivos Therapeutics, Inc. a larger multi-site path to repeat purchases and quicker adoption.
Adults with OSA or snoring
Adults with OSA or loud snoring are Vivos Therapeutics, Inc.’s core end users: global research estimates about 936 million adults aged 30-69 have mild-to-severe OSA, and roughly 425 million have moderate-to-severe disease. Demand is driven by better sleep, daytime function, and reduced quality-of-life pain points.
- Primary users: adult OSA and snoring patients
- Large addressable need: 936 million adults
- Value driver: sleep quality and daily function
Children needing screening
Vivos Therapeutics, Inc. uses VivoScore to screen children as well as adults, so pediatric screening adds a second end-user pool and widens early sleep-disorder detection. Pediatric obstructive sleep apnea affects about 1% to 4% of children, which supports a larger screening need beyond adult cases.
- Children are a separate screening segment
- VivoScore reaches early sleep-issue detection
- Large pediatric need, 1% to 4%
Vivos Therapeutics: Scaling OSA Care Through Dentists and DSOs
Vivos Therapeutics, Inc. serves two main customer groups in 2025: licensed dentists and other medical providers who screen, fit, and monitor treatment, and patients with OSA or chronic snoring who drive demand. The biggest channel lever is DSOs, which cover about 20% of U.S. dentists and can scale adoption across multiple sites.
| Segment | 2025 data |
|---|---|
| Dentists | 200,000+ U.S. |
| DSOs | About 20% of dentists |
| Adults with OSA | 936 million global |
| Children with OSA | 1% to 4% |
Cost Structure
Research and development
Research and development is a core cash use for Vivos Therapeutics, Inc. because medical technology needs constant product refinement, testing, and clinical validation. These outlays support its treatment platform and screening services, so each new study and design update can improve adoption and clinician trust.
Sales and marketing
Sales and marketing is a major cost for Vivos Therapeutics, Inc. because provider acquisition and market education need ongoing commercial spend on sales coverage, promo materials, and lead generation. In a specialty medical device model, this line item often sits in SG&A and can scale with revenue growth as the company expands clinician awareness and referrals.
Clinical training support
Clinical training support is a recurring cost for Vivos Therapeutics, Inc. because onboarding and education do not stop at the sale; providers need follow-up so the appliance is used correctly and patients stay on therapy. That spend supports adoption and retention, and in fiscal 2025 it sat alongside the company’s wider support and sales effort, where every added provider can also mean more training touchpoints.
Manufacturing and logistics
Vivos Therapeutics, Inc. must manufacture, package, and ship its oral-appliance systems, so manufacturing and logistics sit in cost of goods sold. These costs scale with provider count across the U.S. and Canada, and wider distribution means more freight, warehousing, and channel-support spend.
- Production and packaging are core costs
- Cross-border delivery adds freight expense
- Broader reach raises logistics overhead
SG and A, compliance
Vivos Therapeutics, Inc. keeps SG&A and compliance heavy because a regulated healthcare model needs corporate staff, quality control, and legal oversight at all times. These costs are mostly fixed, so they rise with scale and can pressure margins when revenue is still small.
- Corporate overhead is recurring
- Compliance adds fixed labor cost
- Quality rules lift cash spend
Vivos Therapeutics: Heavy Fixed Costs Make Scale the Key to Margin Gains
Vivos Therapeutics, Inc. cost structure is driven by R&D, sales and marketing, clinical training, and regulated manufacturing, with SG&A and compliance adding a mostly fixed overhead base. In fiscal 2025, these costs stayed tied to provider education, product refinement, and appliance shipping, so scale matters more than one-off volume gains.
| Cost item | Role |
|---|---|
| R&D | Product and clinical validation |
| Sales and marketing | Provider acquisition and education |
| Manufacturing and logistics | COGS and shipping |
Revenue Streams
Vivos System sales
Vivos Therapeutics, Inc. earns most of its revenue from Vivos System sales, sold through licensed medical professionals, mainly dentists. This is the company’s main product-based income stream, so growth depends on provider adoption and patient starts.
Replacement appliance sales
Replacement appliance sales let Vivos Therapeutics monetize ongoing treatment, since patients may need new or related appliances as therapy continues. This creates repeat demand and recurring revenue from the installed provider base, turning each active clinic into a longer-lived sales channel.
VivoScore fees
VivoScore fees add service revenue by pairing comprehensive screening with home sleep tests, so Vivos Therapeutics, Inc. earns beyond device sales. This model gives the Company a recurring, care-based income stream and ties revenue to each patient screening, not just one-time product delivery.
Home sleep test revenue
Home sleep test revenue gives Vivos Therapeutics, Inc. a separate, billable diagnostic line, so the Company can earn before treatment starts. With obstructive sleep apnea affecting about 30 million U.S. adults and most cases still undiagnosed, convenient at-home testing helps identify patients and lift conversion into care.
Separate diagnostic billing supports revenue.
Home tests improve patient access and screening.
More diagnoses can drive treatment conversion.
Related professional services
Related professional services add recurring revenue through provider training, onboarding, and implementation support, helping clinicians adopt the Vivos Therapeutics system correctly. In Vivos Therapeutics, Inc.'s latest 2025 public filings, these services were not broken out as a separate revenue line, but they remain important for post-sale retention and deeper customer ties.
- Provider training supports adoption
- Implementation helps clinic workflow
- Post-sale service deepens loyalty
Vivos Revenue Is Still Driven by Device Sales
Vivos Therapeutics, Inc. monetizes treatment mainly through Vivos System sales, replacement appliances, VivoScore screening fees, home sleep tests, and provider services. In its 2025 filings, these service revenues were not broken out separately, so the mix still centers on device-led sales.
| Stream | Revenue role |
|---|---|
| Vivos System | Main product sales |
| Tests and fees | Recurring diagnostic income |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.